These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. Nishijima TF; Shachar SS; Nyrop KA; Muss HB Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115 [TBL] [Abstract][Full Text] [Related]
27. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials. Shi Y; Duan J; Guan Q; Xue P; Zheng Y Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922 [TBL] [Abstract][Full Text] [Related]
28. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? Zhang Y; Zhou H; Zhang L J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312 [TBL] [Abstract][Full Text] [Related]
29. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review. Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224 [TBL] [Abstract][Full Text] [Related]
33. Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond. Dallos MC; Drake CG Cancer J; 2018; 24(1):20-30. PubMed ID: 29360724 [TBL] [Abstract][Full Text] [Related]
34. Programmed cell death protein receptor and ligands in haematological malignancies - Current status. Sokołowski M; Sokołowska A; Mazur G; Butrym A Crit Rev Oncol Hematol; 2019 Mar; 135():47-58. PubMed ID: 30819446 [TBL] [Abstract][Full Text] [Related]
35. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study. Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011 [TBL] [Abstract][Full Text] [Related]
36. Cancer immunotherapy: The dark side of PD-1 receptor inhibition. Ludin A; Zon LI Nature; 2017 Dec; 552(7683):41-42. PubMed ID: 29143822 [TBL] [Abstract][Full Text] [Related]
37. Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression? Saleh K; Khalifeh-Saleh N; Kourie HR Immunotherapy; 2018 Apr; 10(5):345-347. PubMed ID: 29473468 [No Abstract] [Full Text] [Related]
38. Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. Lurain K; Ramaswami R; Yarchoan R; Uldrick TS Curr HIV/AIDS Rep; 2020 Oct; 17(5):547-556. PubMed ID: 32827111 [TBL] [Abstract][Full Text] [Related]
39. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]. Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296 [TBL] [Abstract][Full Text] [Related]
40. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]